A5079307750- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Hepatitis B Virus Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Polyomavirus and related diseases
- Interprofessional Education and Collaboration
- Patient-Provider Communication in Healthcare
- Family and Disability Support Research
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
- Bladder and Urothelial Cancer Treatments
- Palliative Care and End-of-Life Issues
- Urinary Tract Infections Management
- Patient Dignity and Privacy
- Immunotherapy and Immune Responses
- Peripheral Artery Disease Management
- Urinary Bladder and Prostate Research
- Nursing Diagnosis and Documentation
- Cardiovascular Syncope and Autonomic Disorders
- Amyotrophic Lateral Sclerosis Research
- Aging, Health, and Disability
- Antiplatelet Therapy and Cardiovascular Diseases
- Hepatitis Viruses Studies and Epidemiology
- Social Sciences and Policies
- Health and Medical Education
Vall d'Hebron Institut de Recerca
2023-2024
University of Girona
2020-2024
Vall d'Hebron Hospital Universitari
2022-2024
Centre d'Esclerosi Múltiple de Catalunya
2022-2023
Universitat Autònoma de Barcelona
2023
Biogen (United States)
2020
E Ink (South Korea)
2020
Ashfield Healthcare
2020
Clínica Girona
2020
Institut d'Investigació Biomèdica de Girona
2014-2015
Abstract Introduction Prospective data on the risk of hepatitis B reactivation (HBVr) among patients with resolved HBV infection undergoing anti-CD20 antibodies monotherapy is scarce . We aimed to assess HBVr in treated rituximab or ocrelizumab for multiple sclerosis (MS) neuromyelitis optica spectrum disorder (NMOSD) without antiviral prophylaxis. Methods HEBEM a prospective study that included all consecutive adults HBsAg-negative/anti-HBc-positive who initiated MS NMOSD at Cemcat....
ABSTRACT BACKGROUND: Multiple sclerosis (MS) affects approximately 50 000 people in Spain, so it is essential to implement health interventions that respond their needs and demands. Expert patient programs may facilitate health-related empowerment through peer learning, but particular features need be tailored MS. METHODS: Qualitative research was used examine the demands of with MS relation management aim designing a specific program enable empowerment. Data gathered from focus group...
Multiple sclerosis (MS) causes a progressive disability, which substantially impacts the quality of life (QoL). Health interventions that meet needs and demands people with MS are essential to minimize QoL impairment. Expert patient programs (EPPs) facilitate health-related empowerment through peer learning. Based on previous focus group study, we designed an EPP for coordinated by nursing professionals implementation in different reference units Catalonia (Southwestern Europe). This study...
Gastrointestinal (GI) adverse events (AEs) are commonly encountered with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing multiple sclerosis (MS).Two hundred thirty-nine MS nurses from 7 countries were asked to complete a 2-round Delphi survey developed by 7-member steering committee. Questions pertained approaches mitigating DMF-associated GI AEs.Ninety-six percent of followed the label recommendation DMF dose titration in round 1, but 77% titrated more slowly...
ABSTRACT BACKGROUND: Patients with multiple sclerosis (MS) may experience decisional conflict during treatment choice. Shared decision making (SDM), whereby patients and health professionals, primarily nurses, collaborate in decisions, reduces this conflict. It requires understanding large amounts of information be complex, especially when decisions affect patients' autonomy quality prolongation life. Patient aids are tools facilitating SDM. This study aimed to identify the key elements from...
Spasticity is a frequent symptom of multiple sclerosis (MS), which may negatively influence daily living activities (ADL).To (1) explore the feasibility to conduct structured interview by specialist nurses about limitations in ADL; (2) determine percentage people with MS (PwMS) ADL related spasticity; (3) assess knowledge spasticity and describe its clinical features.Observational, cross-sectional, multicentre study 16 units Catalonia (Spain). Participants were recruited from outpatient...
ABSTRACT Timely diagnosis of multiple sclerosis (MS) is a challenge due to factors such as prompt identification symptoms and consequent delays in hospital visits treatment initiation. In part address this challenge, an expert scientific advisory panel clinical nurse practitioners (CNPs) from different European nations was convened by Viatris on October 25, 2022, Amsterdam, the Netherlands. This meeting interactive discussion understand role MS management. The objectives were (1) current...
Multiple sclerosis (MS) is a chronic degenerative disease of the central nervous system with an autoimmune inflammatory basis that presents clinical variability and progressive disability. The most common type MS relapsing remitting pattern affects 85% patients from onset. Relapses are characterised by acute new episodes inflammation can cause neurological deficit followed period recovery remission. Patients may not make full relapse be left ongoing ‘background’ symptoms require symptom...